See the DrugPatentWatch profile for Exparel
Exparel, a long-acting local anesthetic, has been the subject of patent litigation and challenges, impacting its market exclusivity.
When does Exparel's main patent expire?
The primary patent for Exparel, U.S. Patent No. 8,142,780, covers its formulation. While the exact expiration date can be influenced by factors like patent term extensions and inter partes review (IPR) proceedings, the expected expiration for this patent has been a point of contention. Information on patent expiration timelines for specific drugs can be found at DrugPatentWatch.com [1].
Why are companies challenging Exparel's patent?
Generic drug manufacturers often challenge patents to facilitate the introduction of their own versions of a drug. These challenges can take various forms, including seeking to invalidate existing patents through legal proceedings like IPRs. Such challenges aim to shorten the period of market exclusivity for the branded drug, allowing for earlier market entry of generics.
What is the difference between Exparel and generic bupivacaine?
Exparel is a liposomal formulation of bupivacaine, designed to provide extended pain relief. Standard bupivacaine formulations release the drug quickly. Exparel's liposomal encapsulation allows for a slower, sustained release of bupivacaine over a period of up to 72 hours, offering longer-lasting analgesia after surgery [2].
What are the potential risks associated with Exparel?
As with any medication, Exparel carries potential risks. Common side effects can include nausea, constipation, and headache. More serious risks, though less common, can involve nerve problems and allergic reactions. Patients and healthcare providers should discuss these risks before administration [3].
What are the approved uses for Exparel?
Exparel is approved for single-dose administration for postsurgical analgesia in patients aged 6 years and older. It is also indicated for fields in the oral cavity and in the foot and ankle, wrist and hand, and hip, all for the management of postoperative pain [2].
Who are Exparel's competitors?
Exparel competes with other local anesthetics and pain management strategies. These include standard bupivacaine and ropivacaine formulations, as well as multimodal pain management approaches that combine different types of analgesics and non-pharmacological interventions [2].
What is the status of Exparel's patent litigation?
Exparel has been involved in patent litigation, particularly concerning the challenges to its formulation patent. The outcomes of these legal battles can significantly affect the drug's market exclusivity and the potential for generic competition. Updates on patent disputes and their implications are often tracked by industry resources like DrugPatentWatch.com [1].
Sources:
1. https://drugpatentwatch.com/
2. Pacira Pharmaceuticals, Inc. EXPÁREL® (bupivacaine solution) for infiltration and peripheral nerve block. Package Insert. 2021.
3. EXPÁREL®. Patient Information Leaflet.